S&P 500   3,381.05 (+0.02%)
DOW   27,895.31 (-0.29%)
QQQ   272.85 (+0.36%)
AAPL   458.75 (+1.48%)
MSFT   210.31 (+0.54%)
FB   260.76 (+0.33%)
GOOGL   1,524.26 (+1.13%)
AMZN   3,211.98 (+1.57%)
NVDA   463.37 (+1.26%)
CGC   17.44 (+1.10%)
BABA   254.66 (-0.21%)
TSLA   1,607.64 (+3.40%)
GE   6.67 (-0.74%)
MU   46.30 (-4.50%)
AMD   83.21 (+0.73%)
T   30.02 (-0.53%)
F   7.14 (+0.42%)
ACB   9.69 (-1.12%)
GILD   68.33 (-0.74%)
NFLX   481.21 (+1.21%)
DIS   131.85 (+0.05%)
BAC   26.26 (-1.76%)
BA   177.79 (+1.34%)
S&P 500   3,381.05 (+0.02%)
DOW   27,895.31 (-0.29%)
QQQ   272.85 (+0.36%)
AAPL   458.75 (+1.48%)
MSFT   210.31 (+0.54%)
FB   260.76 (+0.33%)
GOOGL   1,524.26 (+1.13%)
AMZN   3,211.98 (+1.57%)
NVDA   463.37 (+1.26%)
CGC   17.44 (+1.10%)
BABA   254.66 (-0.21%)
TSLA   1,607.64 (+3.40%)
GE   6.67 (-0.74%)
MU   46.30 (-4.50%)
AMD   83.21 (+0.73%)
T   30.02 (-0.53%)
F   7.14 (+0.42%)
ACB   9.69 (-1.12%)
GILD   68.33 (-0.74%)
NFLX   481.21 (+1.21%)
DIS   131.85 (+0.05%)
BAC   26.26 (-1.76%)
BA   177.79 (+1.34%)
S&P 500   3,381.05 (+0.02%)
DOW   27,895.31 (-0.29%)
QQQ   272.85 (+0.36%)
AAPL   458.75 (+1.48%)
MSFT   210.31 (+0.54%)
FB   260.76 (+0.33%)
GOOGL   1,524.26 (+1.13%)
AMZN   3,211.98 (+1.57%)
NVDA   463.37 (+1.26%)
CGC   17.44 (+1.10%)
BABA   254.66 (-0.21%)
TSLA   1,607.64 (+3.40%)
GE   6.67 (-0.74%)
MU   46.30 (-4.50%)
AMD   83.21 (+0.73%)
T   30.02 (-0.53%)
F   7.14 (+0.42%)
ACB   9.69 (-1.12%)
GILD   68.33 (-0.74%)
NFLX   481.21 (+1.21%)
DIS   131.85 (+0.05%)
BAC   26.26 (-1.76%)
BA   177.79 (+1.34%)
S&P 500   3,381.05 (+0.02%)
DOW   27,895.31 (-0.29%)
QQQ   272.85 (+0.36%)
AAPL   458.75 (+1.48%)
MSFT   210.31 (+0.54%)
FB   260.76 (+0.33%)
GOOGL   1,524.26 (+1.13%)
AMZN   3,211.98 (+1.57%)
NVDA   463.37 (+1.26%)
CGC   17.44 (+1.10%)
BABA   254.66 (-0.21%)
TSLA   1,607.64 (+3.40%)
GE   6.67 (-0.74%)
MU   46.30 (-4.50%)
AMD   83.21 (+0.73%)
T   30.02 (-0.53%)
F   7.14 (+0.42%)
ACB   9.69 (-1.12%)
GILD   68.33 (-0.74%)
NFLX   481.21 (+1.21%)
DIS   131.85 (+0.05%)
BAC   26.26 (-1.76%)
BA   177.79 (+1.34%)
Log in

NASDAQ:AUPHAurinia Pharmaceuticals Stock Price, Forecast & News

$14.03
-0.15 (-1.06 %)
(As of 08/13/2020 11:13 AM ET)
Add
Compare
Today's Range
$13.92
Now: $14.03
$14.30
50-Day Range
$13.19
MA: $14.82
$16.66
52-Week Range
$3.52
Now: $14.03
$21.93
Volume14,268 shs
Average Volume1.59 million shs
Market Capitalization$1.77 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.18
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
Read More
Aurinia Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.63 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AUPH
CUSIPN/A
Phone250-708-4272

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$320,000.00
Book Value$2.45 per share

Profitability

Net Income$-123,850,000.00
Net Margins-43,965.98%

Miscellaneous

Employees39
Market Cap$1.77 billion
Next Earnings Date11/12/2020 (Estimated)
OptionableOptionable
$14.03
-0.15 (-1.06 %)
(As of 08/13/2020 11:13 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AUPH News and Ratings via Email

Sign-up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aurinia Pharmaceuticals (NASDAQ:AUPH) Frequently Asked Questions

How has Aurinia Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Aurinia Pharmaceuticals' stock was trading at $14.10 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AUPH stock has decreased by 0.4% and is now trading at $14.05.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Aurinia Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aurinia Pharmaceuticals
.

When is Aurinia Pharmaceuticals' next earnings date?

Aurinia Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Aurinia Pharmaceuticals
.

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) released its earnings results on Tuesday, August, 11th. The biotechnology company reported ($0.26) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.03. Aurinia Pharmaceuticals had a negative net margin of 43,965.98% and a negative return on equity of 40.66%.
View Aurinia Pharmaceuticals' earnings history
.

What price target have analysts set for AUPH?

9 Wall Street analysts have issued 1-year price objectives for Aurinia Pharmaceuticals' stock. Their forecasts range from $14.00 to $34.00. On average, they anticipate Aurinia Pharmaceuticals' stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 70.8% from the stock's current price.
View analysts' price targets for Aurinia Pharmaceuticals
.

Has Aurinia Pharmaceuticals been receiving favorable news coverage?

Media coverage about AUPH stock has been trending extremely negative on Thursday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aurinia Pharmaceuticals earned a news impact score of -4.1 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term.
View the latest news about Aurinia Pharmaceuticals
.

Are investors shorting Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals saw a decrease in short interest in February. As of February 15th, there was short interest totaling 4,510,000 shares, a decrease of 11.9% from the January 31st total of 5,120,000 shares. Based on an average daily volume of 3,510,000 shares, the short-interest ratio is presently 1.3 days. Approximately 5.5% of the shares of the stock are short sold.
View Aurinia Pharmaceuticals' Short Interest
.

Who are some of Aurinia Pharmaceuticals' key competitors?

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Array Biopharma (ARRY), Alibaba Group (BABA) and Corbus Pharmaceuticals (CRBP).

Who are Aurinia Pharmaceuticals' key executives?

Aurinia Pharmaceuticals' management team includes the following people:
  • Mr. Michael R. Martin, Co-Founder & COO
  • Mr. Dennis Bourgeault CPA, C.A., CFO & Sec.
  • Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
  • Dr. Richard M. Glickman, Advisor (Age 61)
  • Dr. Neil Solomons M.D., Chief Medical Officer

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Who are Aurinia Pharmaceuticals' major shareholders?

Aurinia Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.79%), Hudson Bay Capital Management LP (0.30%), Goldman Sachs Group Inc. (0.21%), Bank of Montreal Can (0.17%), Swiss National Bank (0.14%) and BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp (0.13%).

Which institutional investors are selling Aurinia Pharmaceuticals stock?

AUPH stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Assenagon Asset Management S.A., Hudson Bay Capital Management LP, UBS Group AG, and Patriot Financial Group Insurance Agency LLC.

Which institutional investors are buying Aurinia Pharmaceuticals stock?

AUPH stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, Alps Advisors Inc., Knott David M, CIBC Asset Management Inc, Bailard Inc., Swiss National Bank, and Ensign Peak Advisors Inc.

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aurinia Pharmaceuticals' stock price today?

One share of AUPH stock can currently be purchased for approximately $14.05.

How big of a company is Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals has a market capitalization of $1.77 billion and generates $320,000.00 in revenue each year. The biotechnology company earns $-123,850,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Aurinia Pharmaceuticals employs 39 workers across the globe.

What is Aurinia Pharmaceuticals' official website?

The official website for Aurinia Pharmaceuticals is www.auriniapharma.com.

How can I contact Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-708-4272 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.